Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail shows promise for rare bone cancer

NCT ID NCT03011528

Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a more intense chemotherapy plan for people aged 2 to 50 with Ewing sarcoma that has spread beyond the lungs. The goal was to see if this approach could help more patients become cancer-free for at least 18 months. The treatment combined high-dose chemotherapy with a stem cell transplant to try to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

45 people

The number who actually took part.

Started

Dec 2016

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \- Ewing tumour histologically or cytologically confirmed, harboring a specific transcript, and with extrapulmonary metastases (including nodal extension) - histology and FISH results must be consistent, specific transcript can be obtained after inclusions. 2. \- Ewing tumour not previously treated. 3. \- Age between 2 and 50 years. 4. \- Measurable disease by cross sectional imaging (RECIST 1.1) or evaluable disease with functional metabolic, positron emission tomography scanner (PET SCAN) or other methods (e.g., cytology/histology). 5. \- General status compatible with the study treatments (LANSKY score ≥ 50%, or Karnofsky ≥ 50%, or Eastern Cooperative Oncology Group (ECOG) ≤ 2). 6. \- Adequate bone marrow function (not applicable in case of bone marrow disease). * Platelets ≥ 100 x 109 /L * Absolute Neutrophil Count (ANC) ≥ 1 x 109 /L * Hemoglobin ≥ 8g /dL. 7. \- Adequate liver function : * Aspartate Aminotransferase (AST) and Alanine Transferase (ALT) ≤ 5 x Upper Limit Normal (ULN) * Total Bilirubin ≤ 2 Upper Limit Normal (ULN). If total bilirubin \> 2xULN, Bilirubin Conjugated Fraction (BCF) ≤ 2 x ULN 8. \- No absolute contra-indication of Busulfan-Melphalan if radiotherapy of the primary tumour is necessary with specific attention to patient with primary spinal tumor. 9. \- Adequate cardiac and renal functions: * Creatinine \< 1.5 of normal for age or clearance \> 60 ml/min/1.73 m²; * Left Ventricular Ejection Fraction (LVEF) \> 50% and/or shortening fraction \> 28%. 10. \- No underlying disease contra-indicating the study treatments. 11. \- Patient likely compliant with the recommended study medical monitoring during and after treatments. 12. \- Patients of childbearing potential must agree to use adequate contraception for the duration of study treatments and up to 12 months for women and 6 months for men following completion of therapy. 13. \- Females of childbearing potential must have a negative serum β-human chorionic gonadotropin (HCG) pregnancy test within 10 days prior study inclusion, and/or urine pregnancy test within 48 hours before the first administration of the study treatment. 14. \- Patients covered by a health insurance system. 15. \- Patient, or patient's legal representative, informed and having signed the informed consent. Exclusion Criteria: 1. \- Age below 2 or greater than 50 years. 2. \- Ewing tumour localized, or solely with pleural and/or lung metastases. 3. \- Concomitant disease, particularly infectious disease, likely to interfere with patient's treatment. 4. \- History of cancer, according to investigator's judgment. 5. \- Life expectancy \< 2 months. 6. \- Patient already included in another clinical trial with an investigational drug. 7. \- Pregnant or breastfeeding patient. 8. \- Person deprived of liberty or under guardianship. 9. \- Patient likely unable to comply with the study medical monitoring for geographical, social or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ewing sarcoma family of tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ewing sarcoma Ewing sarcoma/peripheral primitive neuroectodermal tumor Neuroectodermal Tumors, Primitive, Peripheral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ewing sarcoma family of tumors

Contacts and locations

Locations

  • Bordeaux Chu

    Bordeaux, 33076, France

  • CHRU Montpellier - Hôpital A. de Villeneuve

    Montpellier, 34295, France

  • CHU Grenoble Alpes

    Grenoble, 38043, France

  • CHU Hôpital Sud

    Rennes, 35056, France

  • Chr Felix Guyon

    La Réunion, Saint Denis, 97400, France

  • LILLE Centre Oscar Lambret

    Lille, 59000, France

  • LYON Centre Léon Bérard

    Lyon, 69000, France

  • Marseille Chu

    Marseille, 13000, France

  • NANCY Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

  • Nancy Chu

    Vandœuvre-lès-Nancy, 54511, France

  • Nantes Chu

    Nantes, 44000, France

  • PARIS Institut Curie

    Paris, 75005, France

  • PARIS Trousseau

    Paris, 75012, France

  • Strasbourg Chu

    Strasbourg, 67098, France

  • TOULOUSE Institut Claudius Regaud

    Toulouse, 31059, France

  • Toulouse Chu

    Toulouse, 31059, France

  • VILLEJUIF Institut Gustave Roussy

    Villejuif, 94805, France